Page 1 of 1 FORM PTO 1449 (modified) ATTY DOCKET NO.: SERIAL NO.: 0.0 (4.00)											
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO:					USOP .	<i>).</i> :	35,	SERIAL NO.: 09/807,647			
					APPLICANT: Satoru OI et al.						
					FILING DATE: 4/16/01			GROUP: 1624			
WELL SEED TO SEE TO SEE TO SEE THE SEED OF											
EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE		NAME	CLAS	SS-	SUBCLASS	FILING I APPROPI		
B.K.	A1 .	5,859,007	Jan. 12, 1999		C. J. Aquino et al.						
S.K.	A2	5,910,495	Jun. 8, 1999		R. M. Hanley						
The state of the s				V 9 1 9 2 1 1 1							
*EXAMINER	REF	DOCUMENT	FOREIG		FENE DOCUM			SUBCLASS		ATION	
INITIAL	No.	NUMBER				2234			YES	NO	
DK.	A3	WO 98/47882	Oct. 29, 1	998	WO	14 mil 42 mil	(
					·						
-											
	ļ		-					-			
]				
EXAMINER INITIAL	REF. No.				TITLE, DATE,			4.15.25			
D.K.	A4	C. Papageorgiou et al. "A Non-peptide ligand for the somatostatin receptor having a benzodiazepinone structure", Bioorganic & Medicinal Chemistry Letters, Vol. 6(1996), No. 3, pp. 267-272									
B.K.	A5	P. Shah et al. "Novel 1,5-benzodiazepindione Gastrin/CCKB Antagonists", Bioorganic & Medicinal Chemistry Letters, Vol. 7(1997), No. 3, pp.281-286									
A.K.	A6	B. R. Henke et al. "Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists", Journal of Medicinal Chemistry, Vol. 40(1997), No. 17, pp. 2706-2725									
EXAMINER:	L.,		211	<u></u>	ATE CONSIDE	.तबव		, 			
EXAMINER: DATE CONSIDERED: 6/14/05											

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.